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Introduction
Certolizumab pegol (CZP) has a different mode of action
from the other anti-TNFs, infliximab (IFX), adalimumab
(ADA) and etanercept (ETA), that may be due both to its
structure and how it signals through membrane TNF-a
(mTNF-a). Different effects of this signalling could relate
to the exact epitopes to which the anti-TNFs bind. We
investigated the binding epitope for CZP and how it dif-
fers from the other anti-TNFs.
Methods
Epitope mapping for CZP binding to TNF was achieved
using minimal shift analysis of nuclear magnetic reso-
nance) data on the non-PEGylated Fab′/TNF complex.
Hydrogen/deuterium (H/D) exchange mass spectrometry
was used to identify TNF peptides containing amide pro-
tons that are protected in the Fab′/TNF complex. A Bia-
core assay was used to determine the difference in affinity
between cynomolgus monkey and human TNF for each of
the 4 anti-TNFs. This technique involved the use of cross-
species mutagenesis of the 4 residues that differ between
cynomolgus monkey and human TNF (V37L, T44R,
N72T, L138R). The epitope identified by these methods
was confirmed by further site-directed mutagenesis and
Biacore-based studies.
Results
13 amino acids (E19, A22, E23, G24, Q25, Q27, L43, R44,
D45, N46, Q47, I83, R138) were identified as comprising
the CZP epitope on TNF. These residues formed a cluster
on the outer face of each monomer. Biacore studies on
TNF peptides expressed with these residues mutated
showed that, although there was some overlap, the pattern
of binding for each of the anti-TNFs was different.
Conclusions
All 4 anti-TNFs tested bind to similar but not identical
epitopes on the TNF molecule. These differences between
the exact epitope could explain the variations in the down-
stream signalling properties through mTNF-a of the anti-
TNFs and may help to elucidate some of the mode of
action differences emerging for these agents.
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